•  
  •  
 

Turkish Journal of Medical Sciences

DOI

10.3906/sag-1101-1470

Abstract

Aim: To study the combination treatment consisting of half-dose verteporfin photodynamic therapy (PDT) and an intravitreal injection of ranibizumab as a potential treatment for patients with chronic central serous chorioretinopathy (CSC). Materials and methods: Six eyes of 6 patients were studied with fundus examination, fluorescein angiography, and optical coherence tomography to diagnose the maculopathy, monitor the detachments, and localize the choroidal hyperpermeability of the disorder. Half-dose verteporfin PDT was applied to areas of choroidal hyperpermeability and, the following day, 0.5 mg/0.05 mL ranibizumab was injected intravitreally. The patients were observed to determine the anatomic and functional outcomes. Results: The combination therapy consisting of half-dose verteporfin PDT and intravitreal injection of ranibizumab was associated with complete resolution of the exudative macular detachments in all of the patients. Vision improved in the 6 eyes and remained unchanged during the follow-up examinations, for at least more than 6 months. At 4 weeks after treatment, the best corrected visual acuity had improved to 20/20 in 5 of the cases. None of the patients had any treatment-related side effects. Conclusion: The combination therapy consisting of half-dose verteporfin PDT and intravitreal injection of ranibizumab seems to result in the resolution of exudative detachments in patients with chronic CSC. This treatment caused a rapid reduction in subretinal fluid and improvement in visual acuity. Although the follow-up time and the number of patients in this study were limited, the encouraging results and lack of complications suggest the value of further study.

Keywords

Central serous chorioretinopathy, intravitreal ranibizumab, photodynamic therapy

First Page

681

Last Page

688

Download

Share

COinS